Financial Survey: Marrone Bio Innovations (MBII) and Its Competitors
Marrone Bio Innovations (NASDAQ: MBII) is one of 27 publicly-traded companies in the “Agricultural Chemicals” industry, but how does it compare to its rivals? We will compare Marrone Bio Innovations to related companies based on the strength of its valuation, risk, earnings, profitability, analyst recommendations, dividends and institutional ownership.
This table compares Marrone Bio Innovations and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Marrone Bio Innovations||-177.10%||N/A||-64.21%|
|Marrone Bio Innovations Competitors||-398.58%||-14.98%||-9.25%|
Volatility & Risk
Marrone Bio Innovations has a beta of 0.29, indicating that its stock price is 71% less volatile than the S&P 500. Comparatively, Marrone Bio Innovations’ rivals have a beta of 0.94, indicating that their average stock price is 6% less volatile than the S&P 500.
This is a breakdown of current ratings and price targets for Marrone Bio Innovations and its rivals, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Marrone Bio Innovations||0||2||1||0||2.33|
|Marrone Bio Innovations Competitors||214||818||910||34||2.39|
Marrone Bio Innovations currently has a consensus target price of $2.50, suggesting a potential upside of 111.86%. As a group, “Agricultural Chemicals” companies have a potential upside of 1.05%. Given Marrone Bio Innovations’ higher possible upside, analysts clearly believe Marrone Bio Innovations is more favorable than its rivals.
Insider and Institutional Ownership
39.0% of Marrone Bio Innovations shares are owned by institutional investors. Comparatively, 47.5% of shares of all “Agricultural Chemicals” companies are owned by institutional investors. 7.3% of Marrone Bio Innovations shares are owned by insiders. Comparatively, 22.4% of shares of all “Agricultural Chemicals” companies are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Valuation & Earnings
This table compares Marrone Bio Innovations and its rivals top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Marrone Bio Innovations||$16.95 million||-$21.12 million||-1.01|
|Marrone Bio Innovations Competitors||$3.75 billion||$757.56 million||14.56|
Marrone Bio Innovations’ rivals have higher revenue and earnings than Marrone Bio Innovations. Marrone Bio Innovations is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
Marrone Bio Innovations rivals beat Marrone Bio Innovations on 9 of the 12 factors compared.
Marrone Bio Innovations Company Profile
Marrone Bio Innovations, Inc. offers bio-based pest management and plant health products. The Company’s bio-based products include naturally occurring microorganisms, such as bacteria, fungi and plant extracts. It sells its products to crop protection market. Its four crop protection products include Regalia, Grandevo, Venerate and Majestene. Its products are used in both conventional and organic crop production, and are sold to growers of specialty crops, such as grapes, citrus, tomatoes, vegetables, nuts, leafy greens and ornamental plants. It offers Regalia for large-acre row crops, such as corn and soybeans. Its pipeline of early-stage discoveries and product candidates extends across a range of product types for end markets, including herbicides, fungicides, nematicides, insecticides, algaecides (for algae control), molluscicides (for mussel and snail control), and plant growth and plant stress regulators. It is engaged in developing MBI-010, MBI-110, Haven (MBI-505) and MBI-601.
Receive News & Ratings for Marrone Bio Innovations Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marrone Bio Innovations Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.